AML is the most common acute leukemia, with significant chromosomal translocations and mutations in the genes involved in hematopoietic proliferation and differentiation, resulting in the accumulation of poorly differentiated myeloid cells. AML is a highly heterogeneous disease with favorable, intermediate, and adverse-risk groups based on their cytogenetic profile. The prognosis within these categories varies widely. Identifying recurrent genetic mutations, such as FLT3-ITD, NMP1, and CEBPA, ha...

The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation, and maintenance therapy...

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis. The considerable heterogeneity of MF translates into a wide range of outcomes. Given this heterogeneity, risk stratification for individualized management becomes essential in disease treatment. Treatment of MF according to the NCCN treatment guidelines is dependent on several factors—risk stratification, symptom burden, and eligibility for different treatment...